Year End Results

Period Ended December 31, 2023
This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Strategic Partnerships, Collaborations, and Licensing Agreements

As part of Genmab’s Full Year 2023 Results presentation, we will discuss several products developed in collaboration with strategic partners or that are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships.

**Partners for Genmab owned products ≥50%:**
- Pfizer Inc. (Seagen\(^1\)): tisotumab vedotin (Tivdak\(^\circledR\))
- AbbVie Inc.: epcoritamab (EPKINLY™ / TEPKINLY\(^\circledR\))
- BioNTech SE\(^2\): Acasunlimab (GEN1046/BNT311), DuoBody-CD40x4-1BB (GEN1042/BNT312), DuoBody-EpCAMx4-1BB (GEN1059/BNT314), HexaBody-OX40 (GEN1055/BNT315)

**Companies developing products created by Genmab or that incorporate Genmab’s innovation:**
- Janssen Biotech, Inc.: daratumumab, daratumumab and hyaluronidase-fihj (DARZALEX\(^\circledR\), DARZALEX FASPRO\(^\circledR\)), amivantamab (RYBREVANT\(^\circledR\)), teclistamab (TECVAYLI\(^\circledR\)), talquetamab (TALVEY\(^\circledR\))
- Novartis: ofatumumab (Kesimpta\(^\circledR\))
- Amgen\(^3\): teprotumumab (TEPEZZA\(^\circledR\))

---

1. Pfizer closed an acquisition of Seagen on December 14, 2023.
2. Partnership is based on 50:50 profit/loss share
3. Teprotumumab was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Amgen under a license from Roche. Previously teprotumumab was being developed by Horizon Therapeutics plc. Horizon was acquired by Amgen in October 2023.
Evolving Into a Fully Integrated Biotech Innovation Powerhouse: The Genmab Model

- Deep insight into antibody biology & disease targets
- Proprietary technologies enable us to build a world-class pipeline
- Match in-house expertise with strategic collaborations & partnerships
- Strong pipeline of potential first-in-class / best-in-class products

For Investor audience only. Not for public information or use. Not for promotional use.
Approved in U.S., Europe, Japan and other territories¹

- First bispecific antibody in U.S. to treat adults with R/R DLBCL¹
- U.S. FDA granted BTD in R/R FL
- EMA validated Type II variation application in R/R FL
- First and only SC bispecific antibody in Europe to treat adults with R/R DLBCL¹
- First and only bispecific antibody in Japan to treat adults with certain types of R/R LBCL¹
- Added to NCCN Guidelines
- Additional Phase 3 trials expected this year

1. See local prescribing information for full indication and safety information. U.S. FDA accelerated approval; continued approval may be contingent on verification and confirmation of clinical benefit in a confirmatory trial(s).
Expanding Capabilities & Solid Foundation

- Expanding into I&I: argenx collaboration
- Growing recurring revenue streams and significant underlying profitability – 11th consecutive year of profitability
- Focused and disciplined investment approach incl. continued strategic growth of team

Maturing Pipeline

- Tivdak
  - Upgraded to preferred regimen in NCCN Guidelines
  - innovaTV 301 positive topline results, basis of regulatory filings
  - innovaTV 207 interim analysis
  - Planned engagement with health authorities on next steps in head & neck cancer
- Acasunlimab (GEN1046/BNT311)
  - Planned engagement with health authorities on next steps in NSCLC
  - Phase 2 in advanced endometrial cancer

Expanding Pipeline

- Pipeline Progress
  - DuoBody-CD40x4-1BB (GEN1042/BNT312)
  - DuoBody-CD3xB7H4 (GEN1047)
  - DuoBody-CD3xCD30 (GEN3017)

- Next in the clinic
  - DuoBody-EpCAMx4-1BB (GEN1059/BNT314)
  - HexaBody-OX40 (GEN1055/BNT315)

Genmab in 2023: Driving Towards Our 2030 Vision
Other Accomplishments that Strengthen Our Foundation, Support Our Future Success
### Royalty Medicines Portfolio Performance

#### Net sales

<table>
<thead>
<tr>
<th></th>
<th>Q4</th>
<th>FY 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Darzalex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(daratumumab)</td>
<td>$2.55B</td>
<td>$9.74B</td>
</tr>
<tr>
<td><strong>Kesimpta</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ofatumumab)</td>
<td>$0.64B</td>
<td>$2.20B</td>
</tr>
<tr>
<td><strong>TEPEZZA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(teprotumumab-trb)</td>
<td>$0.47B</td>
<td>$1.77B</td>
</tr>
</tbody>
</table>

**Darzalex**
- Leader across lines of therapy; 1L share gains driven by long term OS data
- PERSEUS filed in transplant eligible MM incl maintenance

**Kesimpta**
- Strong US & ex-US growth driven by increased demand and strong access

**Others**
- Tepezza US demand growth/Ex-US expansion plans ongoing
- Tecvayli & Talvey: strong launch momentum in refractory MM
- Rybrevant: MARIPOSA & MARIPOSA-2 filed in Q4 for EGFR mutated NSCLC
# Launch/In-Market Medicines Performance Summary

## Total Worldwide Net sales*

<table>
<thead>
<tr>
<th></th>
<th>Q4</th>
<th>FY 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>epkinly</td>
<td>$36M</td>
<td>$64M</td>
</tr>
<tr>
<td>tivdak</td>
<td>$25M +41% YoY</td>
<td>$90M +42% YoY</td>
</tr>
</tbody>
</table>

## First bispecific antibody approved in US & Japan for B-cell malignancies

- Strong early launch performance in US, Japan & EU
- Leveraged first mover advantage with rapid uptake and adoption
- Launch preparation under way for R/R 3L+ FL potential approval

## Clear answer in 2L+ cervical cancer

- Growth driven by increasing breadth of ordering accounts
- InnovaTV 301 Overall Survival data presented at ESMO Presidential Symposia
- Continued progress with development program across multiple tumor types

---

*Net Product Sales and Collaboration Revenue consists of Epkinly Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S. Collaboration revenue excludes one-off payment in 2022 from Pfizer of approximately USD 15 million (DKK 112 million) related to sublicense of rights to develop and commercialize tisotumab vedotin in China to Zai Lab Hong Kong. This amount is included in Milestone & Reimbursement Revenue for this presentation.
2023: Driving Towards Our 2030 Vision

EPKINLY/TEPKINLY Regulatory Approvals & Launches

22% increase in recurring revenues

Focused Investment: expanding and accelerating our differentiated pipeline and our capabilities

Building the team for continued success
Royalties and Net Product Sales & Collaboration Revenue* Drive 14% YoY Total Revenue Growth

22% Recurring Revenue growth from Royalties and Net Product Sales & Collaboration Revenue

- Higher DARZALEX Royalties from 22% YoY Net Sales growth
- DKK 715M increase in Kesimpta royalties
- DKK 421M in EPKINLY Net Product Sales
- Operational growth 31% (~ 9% unfavorable FX impact)

Milestone and Reimbursement Revenue down DKK 662M due primarily to lower epcoritamab milestones

*In countries where Genmab is the Commercial Lead, we record 100% of the net product sales and record net profit-sharing amounts owed to collaboration partners in Cost of Product Sales.
*In countries where our Partner is the Commercial Lead and we participate in Commercialization efforts, we record Genmab’s share of net profits as Collaboration Revenue.
*In countries where we do not participate in Commercialization efforts, we receive and record Royalty income.
Operating Expense growth of 33%

Securing EPKINLY launch, including building out our 2 key markets – United States and Japan

Advancing Portfolio

- Expanding development programs – EPKINLY, Tivdak, GEN1046, GEN1042
- Early-stage development advancement incl. GEN1047

Investing in world class discovery engine, including move into I&I

Foundational investments in enabling functions achieve required scale
## 2023 Key Figures: Strong Financial Performance

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2022</th>
<th>Change</th>
<th>2023 USD</th>
<th>2022 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DKKM</td>
<td></td>
<td></td>
<td>USD</td>
<td>USD</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>16,474</td>
<td>14,505</td>
<td>1,969</td>
<td>2,443</td>
<td>2,151</td>
</tr>
<tr>
<td>Royalties</td>
<td>13,705</td>
<td>11,582</td>
<td>2,123</td>
<td>2,032</td>
<td>1,717</td>
</tr>
<tr>
<td>Net Product Sales/Collaboration Revenue**</td>
<td>728</td>
<td>220</td>
<td>508</td>
<td>108</td>
<td>33</td>
</tr>
<tr>
<td>Milestone and Reimbursement</td>
<td>2,041</td>
<td>2,703</td>
<td>(662)</td>
<td>303</td>
<td>401</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>16,248</td>
<td>14,505</td>
<td>1,743</td>
<td>2,409</td>
<td>2,151</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>(10,927)</td>
<td>(8,238)</td>
<td>(2,689)</td>
<td>(1,620)</td>
<td>(1,221)</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>5,321</td>
<td>6,267</td>
<td>(946)</td>
<td>789</td>
<td>930</td>
</tr>
<tr>
<td>Net Financial Items</td>
<td>316</td>
<td>678</td>
<td>(362)</td>
<td>47</td>
<td>101</td>
</tr>
<tr>
<td>Tax</td>
<td>(1,285)</td>
<td>(1,493)</td>
<td>208</td>
<td>(191)</td>
<td>(221)</td>
</tr>
<tr>
<td>Net Profit</td>
<td>4,352</td>
<td>5,452</td>
<td>(1,100)</td>
<td>645</td>
<td>810</td>
</tr>
</tbody>
</table>

- 14% increase in revenue & 22% increase in recurring revenue
- 33% growth in investment driven by pipeline expansion and EPKINLY launch activities

*USD 1.00 = DKK 6.7447 (Danish Central Bank spot rate on December 29, 2023)

**Net Product Sales and Collaboration Revenue consists of Epkinly Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S. Collaboration revenue excludes one-off payment in 2022 from Pfizer of approximately USD 15 million (DKK 112 million) related to sublicense of rights to develop and commercialize tisotumab vedotin in China to Zai Lab Hong Kong. This amount is included in Milestone & Reimbursement Revenue for this presentation.
Robust Financial Framework

Recurring Revenue Growth

- 8 approved products generating significant and growing revenues
- Genmab products EPKINLY and Tivdak expanding into additional markets / potential for additional indications
- Continued Royalty revenue growth expected in 2024

Focused Investment

- Accelerating & expanding development of epcoritamab
  - Multiple Phase 3 and other studies to start
  - Investing in EPKINLY launch in U.S. and Japan
- Expanding mid / late-stage development programs – Tivdak, Acasunlimab (GEN1046) and GEN1042
- > 30 in-flight clinical trials anticipated
- Evolving the organization for continued success

Significant Growth Opportunities
# 2024 Guidance Summary

<table>
<thead>
<tr>
<th>YoY Growth Rates</th>
<th>2023</th>
<th>2024*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>14%</td>
<td>19%</td>
</tr>
<tr>
<td>Recurring Revenue</td>
<td>22%</td>
<td>25%</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>33%</td>
<td>18%</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>-15%</td>
<td>10%</td>
</tr>
</tbody>
</table>

*Mid-point of guidance range  
All amounts in DKK millions unless otherwise noted  
2024 guidance assumes a USD/DKK exchange rate of 6.8

- Total revenue growth higher in 2024 and exceeds OPEX growth
- Operating expense growth down significantly YoY in % and DKK terms
- Double digit operating profit growth of 10%
Double digit Revenue Growth in 2024 of ~19%*

DKK 18.7B – 20.5B of revenue expected in 2024

DARZALEX net sales of USD 10.9B to USD 11.5B

~25%* increase in Royalties and Net Product Sales & Collaboration revenue**
- DARZALEX royalties of DKK 12.6B to DKK 13.3B
- Epkinly and Tivdak: Net Product Sales & Collaboration Revenue growth of ~DKK 1.2B

Milestone & Reimbursement Revenue decline driven by fewer milestones anticipated across multiple collaborations

Revenue, DKK Billions

<table>
<thead>
<tr>
<th>Year</th>
<th>Royalties</th>
<th>Net Product Sales &amp; Collaboration Revenue</th>
<th>Milestone &amp; Reimbursement Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>13.7</td>
<td>2.1</td>
<td>0.7</td>
</tr>
<tr>
<td>2024</td>
<td>16.2</td>
<td>1.9</td>
<td>1.5</td>
</tr>
</tbody>
</table>

* Mid-point of guidance range
**Net Product Sales and Collaboration Revenue consists of Epkinly Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S. Collaboration revenue excludes one-off payment in 2022 from Pfizer of approximately USD 15 million (DKK 112 million) related to sublicense of rights to develop and commercialize tisotumab vedotin in China to Zai Lab Hong Kong. This amount is included in Milestone & Reimbursement Revenue for this presentation.

2024 guidance assumes a USD/DKK exchange rate of 6.8
2024 Operating Expense growth expected to be ~18%*

DKK 12.4B – 13.4B in operating expenses expected in 2024

Key near-term investment priorities
- Continued commercialization, development and expansion of EPKINLY
- Acasunlimab, Tivdak, DuoBody-CD40x4-1BB and other pipeline projects

Investing for long-term value creation
- Maximize current technologies
- Next wave of innovative IND candidates

SG&A at scale

For Investor audience only. Not for public information or use. Not for promotional use.
Key Drivers of Investments in 2024* vs. 2023

Portfolio Advancement
- Expanding mid / late-stage development programs – Epcore, Tivdak, Acasunlimab (GEN1046) and GEN1042
- Discovery and Early-stage development advancement
- Team growth to support portfolio advancement

Commercialization
- Continued investment in Epkinly DLBCL launch in US and in Japan; pre-launch activities and investments continue with Epkinly FL in both Markets
- Initiate pre-launch activities for Acasunlimab (1046), 1042 and TV HNSCC
- Solidify Tivdak® in US and prepare for Japan launch

Foundational investments in **enabling functions achieves required scale**
## 2024 Guidance: Double Digit Operating Profit Growth

### Key Figures (DKKM)

<table>
<thead>
<tr>
<th></th>
<th>2023 Actual</th>
<th>2024 Guidance Mid - Point</th>
<th>2024 Guidance</th>
<th>2023 Growth %</th>
<th>2024 Growth %*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>16,474</td>
<td>18,700 – 20,500</td>
<td>19,600</td>
<td>14%</td>
<td>19%</td>
</tr>
<tr>
<td>Royalties</td>
<td>13,705</td>
<td>15,600 – 16,700</td>
<td>16,150</td>
<td>18%</td>
<td>18%</td>
</tr>
<tr>
<td>Net Product Sales/Collaboration Revenue**</td>
<td>728</td>
<td>1,700 – 2,200</td>
<td>1,950</td>
<td>231%</td>
<td>168%</td>
</tr>
<tr>
<td>Milestones/Reimbursement Revenue</td>
<td>2,041</td>
<td>1,400 – 1,600</td>
<td>1,500</td>
<td>-24%</td>
<td>-27%</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>16,248</td>
<td>18,000 – 19,500</td>
<td>18,750</td>
<td>12%</td>
<td>15%</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>(10,927)</td>
<td>(12,400) – (13,400)</td>
<td>(12,900)</td>
<td>33%</td>
<td>18%</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>5,321</td>
<td>4,600 – 7,100</td>
<td>5,850</td>
<td>-15%</td>
<td>10%</td>
</tr>
</tbody>
</table>

*Mid-point of guidance range

**Net Product Sales and Collaboration Revenue consists of Epkinly Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S. Collaboration revenue excludes one-off payment in 2022 from Pfizer of approximately USD 15 million (DKK 112 million) related to sublicense of rights to develop and commercialize tisotumab vedotin in China to Zai Lab Hong Kong. This amount is included in Milestone & Reimbursement Revenue for this presentation.

All amounts in DKK millions unless otherwise noted

2024 guidance assumes a USD/DKK exchange rate of 6.8

---

Genmab Net Product Sales/Collaboration Revenue increasingly contributing to revenue growth

Growth in operating expenses to support expanding mid / late-stage development programs – Epcore, Tivdak, Acasunlimab (GEN1046) and GEN1042

Underlying profitability back to significant growth
Capital Allocation Summary

- Continued Investment in Our Proprietary Pipeline & Technology Platforms
- Pursuing Focused Business Development & M&A Opportunities
- ~USD 500M Share Buyback*

*At the Annual General Meeting on 13 March 2024, the Board of Directors will propose a share buyback program of up to DKK 3.5 billion.
Summary

- Clear path to reach our 2030 Vision
- Growing recurring revenue streams and significant underlying profitability
- Focused and disciplined investment approach
- Significant growth opportunities supported by our Capital allocation Strategy
2024 Priorities:

Bring Our Own Medicines to Patients & Expand Our Markets

EPKINLY¹
• Initiate Three Phase 3 trials
• Expand epicoritamab label to include R/R FL

Tivdak²
• Initiate Phase 3 study in H&N

Execute successful launches & growth in key markets

Further Advancing Our Differentiated Product Pipeline Towards The Market

Build World-class Differentiated Pipeline

Acasunlimab (GEN1046)³
• Initiate Phase 3 study (2L NSCLC)

GEN1042 (DuoBody-CD40x4-1BB)³
• Phase 2 data and determine next steps

Expand and advance proprietary product portfolio

Invest in Our People, Culture & Society

Further scale organization aligned with differentiated antibody product portfolio growth and future launches

Become a Leading Integrated Biotech Innovation Powerhouse

Use solid financial base to grow and broaden antibody product and technology portfolio

¹ Co-development w/ AbbVie; ² Co-development w/ Pfizer; ³ Co-development w/ BioNTech

© Genmab 2024
Upcoming Investor Events

- Genmab Annual General Meeting, March 13, 2024
- UBS European Healthcare Conference, February 28, 2024
- COWEN 44th Annual Healthcare Conference, March 6, 2024